For more ASCO coverage from the CancerNetwork

News
Article

For more American Society of Clinical Oncology coverage from CancerNetwork, please visit our pages Renal Cell Carcinoma (with experts Andrew J Armstrong, MD, MSC, Duke Comprehensive Cancer Center, and Robert J. Motzer, MD, MSKK) and Hematalogic Cancers (coming soon with insights from Samuel M. Silver, MD, PhD, University of Michigan).

For more American Society of Clinical Oncology coverage from CancerNetwork, please visit our pages Renal Cell Carcinoma (with experts Andrew J Armstrong, MD, MSC, Duke Comprehensive Cancer Center, and Robert J. Motzer, MD, MSKK) and Hematalogic Cancers (coming soon with insights from Samuel M. Silver, MD, PhD, University of Michigan).

Recent Videos
Although a greater risk of CNS relapse may emerge with immunotherapy-based backbones, toxicities associated with chemotherapy are avoided.
Current FDA expectations may allow patients to return to their community physicians at 2 weeks after administration of anitocabtagene autoleucel.
Based on its mechanism of action, anito-cel may cause fewer instances of cytokine release syndrome and delayed toxicities vs other therapies.
2 experts are featured in this series.
Once a patient-specific dose is determined, an all-oral combination of revumenib plus decitabine/cedazuridine and venetoclax may be “very good” in AML.
Patients with lung cancer who achieve a complete response with neoadjuvant therapy may not experience additional benefit with adjuvant immunotherapy.
Related Content
Disease Progression Noted After Epcoritamab/Glofitamab in R/R LBCL

Disease Progression Noted After Epcoritamab/Glofitamab in R/R LBCL

Bridget Hoyt
December 11th 2025
Article

“Compared with pivotal trials, epcoritamab and glofitamab continue to be applied in a broad population of patients with high-risk large B-cell lymphoma,” said Taylor R. Brooks, MD.

Why Sexual and Gender Minority Care is an Oncologic Imperative

Why Sexual and Gender Minority Care is an Oncologic Imperative

Daniel C. McFarland, DO;Charles S. Kamen, PhD, MPH
December 8th 2025
Podcast

Daniel C. McFarland, DO, and Charles S. Kamen, PhD, MPH, focused on cultural humility, nonverbal data collection, and tailored resources to improve care.

Zanubrutinib led to a 72% reduction in the risk of disease progression or death vs bendamustine/rituximab in this CLL/SLL population.

Zanubrutinib Exhibits Superior Long-Term Efficacy in First-Line CLL/SLL

Kristi Rosa
December 10th 2025
Article

Zanubrutinib led to a 72% reduction in the risk of disease progression or death vs bendamustine/rituximab in this CLL/SLL population.

Experts highlight considerations for treating patients with oligometastatic kidney cancer, such as differentiating between de novo and recurrent disease.

How to Manage Oligometastatic Kidney Cancer? Insights From IKCS 2025

Manojkumar Bupathi, MD, MS;Benjamin Garmezy, MD
December 4th 2025
Podcast

Experts highlight considerations for treating patients with oligometastatic kidney cancer, such as differentiating between de novo and recurrent disease.

Most CRS events were low grade with elranatamab plus daratumumab and lenalidomide without prophylactic tocilizumab in patients with multiple myeloma.

Tumor Burden Does Not Impact CRS Risk with Elranatamab Combo in Myeloma

Roman Fabbricatore
December 10th 2025
Article

Most CRS events were low grade with elranatamab plus daratumumab and lenalidomide without prophylactic tocilizumab in patients with multiple myeloma.

Giredestrant’s safety in the lidERA BC trial was consistent with its known profile, with a lower discontinuation rate vs SOC endocrine therapy.

Frontline Giredestrant Displays IDFS Improvement vs SOC ET in ER+/HER2– BC

Roman Fabbricatore
December 10th 2025
Article

Giredestrant’s safety in the lidERA BC trial was consistent with its known profile, with a lower discontinuation rate vs SOC endocrine therapy.